The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients

• Status: Recruiting
• Trial end date: 2024-08-08
• Target enrollment: 0
• Participant gender: All

Summary

Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Treatments: Ramipril

Criteria

Inclusion Criteria:

• Patients with mitral valve stenosis or a combination

• aged more than 18 years

• undergo cardiac valve replacement operation with or without a tricuspid valve repair,

• patients with systolic blood pressure (SBP) ≥ 100 mmHg and diastolic blood pressure (DBP) ≥ 60 mmHg

• passed in medication phase without side effect minimum 4 weeks until operation schedule

Exclusion Criteria:

1. Patients with congenital heart disease

2. patients with non-mitral valve surgery

3. patients with coronary artery bypass surgery

4. patients who refuse to join this study.

5. adults aged over 65 years or older

6. pregnant women

7. patients with autoimmune disease.

8. Patients with persistent hypotension (systolic blood pressure (BP) < 100 mm Hg)

9. severe aortic stenosis (aortic valve orifice < 0.75 cm2 )

10. chronic renal dysfunction with serum creatinine > 2.5 mg/ dL,

11. known ACEI intolerance.